ArticleThe Analyst2022
Immunoaffinity monoliths for multiplexed extraction of preterm birth biomarkers from human blood serum in 3D printed microfluidic devices.
Article in The Analyst, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 23 citations in OpenAlex.
- Microscale solid-phase extraction: advances in sorbent formats, system design, integration, and detection methods.Analytical and bioanalytical chemistry · 2026Review
- 3D Printed Microfluidic Devices for Integrated Immunoaffinity Extraction, Solid-Phase Extraction, and Fluorescent Labeling of Preterm Birth Biomarkers.Precision chemistry · 2025Article
- 3D printed microfluidic devices for integrated solid-phase extraction and microchip electrophoresis of preterm birth biomarkers.Analytica chimica acta · 2024Article
- Recent Advances and Challenges in the Early Diagnosis and Treatment of Preterm Labor.Bioengineering (Basel, Switzerland) · 2024Review
- Monolithic affinity columns in 3D printed microfluidics for chikungunya RNA detection.Analytical and bioanalytical chemistry · 2023Article
- Recent Advances on Cell Culture Platforms for In Vitro Drug Screening and Cell Therapies: From Conventional to Microfluidic Strategies.Advanced healthcare materials · 2023Review
- Past, current, and future roles of 3D printing in the development of capillary electrophoresis systems.Trends in analytical chemistry : TRAC · 2023Article
- Labeling on a Chip of Cellular Fibronectin and Matrix Metallopeptidase-9 in Human Serum.Micromachines · 2022Article
- High-Resolution 3D Printing Fabrication of a Microfluidic Platform for Blood Plasma Separation.Polymers · 2022Article
- 3D printed microfluidic device for automated, pressure-driven, valve-injected microchip electrophoresis of preterm birth biomarkers.Mikrochimica acta · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
In an effort to develop biomarker-based diagnostics for preterm birth (PTB) risk, we created 3D printed microfluidic devices with multiplexed immunoaffinity monoliths to selectively extract multiple PTB biomarkers. The equilibrium dissociation constant for each monoclonal antibody toward its target PTB biomarker was determined. We confirmed the covalent attachment of three different individual antibodies to affinity monoliths using fluorescence imaging. Three different PTB biomarkers were successfully extracted from human blood serum using their respective single-antibody columns. Selective binding of each antibody toward its target biomarker was observed. Finally, we extracted and eluted three PTB biomarkers from depleted human blood serum in multiplexed immunoaffinity columns in 3D printed microfluidic devices. This is the first demonstration of multiplexed immunoaffinity extraction of PTB biomarkers in 3D printed microfluidic devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.